Reviewer’s report

Title: Reduced vascular risk in type 2 diabetes by biguanide relative to sulfonylurea: study in Japanese Hospital Database

Version: 2 Date: 11 April 2015

Reviewer: Vaia Lambadiari

Reviewer’s report:

This is an interesting study of Makito Tanabe et al, addressing an interesting issue that could affect every day clinical decision making concerning type 2 antidiabetic treatment in Japan. The paper is easy to read and has clinical implications. Some minor points should be addressed however.

Minor Essential Revisions

1. The authors should make a comment on the study limitations paragraph about the short duration of the follow up. It is not easy to make a safe conclusion about cardiovascular safety when the study period is not long enough.
2. It seems that the percentage of patients within the age range of 60-80 is higher. Could this imply that in the elderly population it is not easy to see cardiovascular prevention with the antidiabetic treatment and the fact that the SU group was older could have affected the results?
3. The group of a-Gl inhibitors starts with a relatively low HbA1c. Could that account for the fact that no benefit was seen in that group, in contrast to other references in the literature?
4. There are too many tables. Could the authors merge some of them?

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests